Method and Device for Detecting Feline Immunodeficiency Virus

Abstract

A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV polypeptides and determining the binding of antibodies in the sample to the polypeptides. The determination of whether an animal is infected with FIV or has been vaccinated against FIV can be determined by measuring the animal's immune response to an FIV env polypeptide. A device for detecting FIV antibodies is provided.

1 - 38 . (canceled) 
     
     
         39 . A method for detecting whether a felid has received a whole killed FIV vaccine that comprises an inactivated FIV Env protein (“FIV vaccine”) or whether the felid is infected with FIV, the method comprising:
 (a) obtaining a biological sample from a felid; 
 (b) contacting the sample with a first antigen consisting of SEQ ID NO:9, consisting of SEQ ID NO:20 or comprising an FIV Env peptide selected from the group consisting of SEQ ID NO:1-8 and 10 under conditions that permit antibody-antigen binding, wherein said first antigen is attached to a solid phase; 
 (c) detecting for antibody-antigen binding, wherein:
 (i) a positive result is indicative of an FIV-infected felid or an uninfected felid that has received the FIV vaccine within about 12 weeks before obtaining the sample; 
 (ii) a negative result is indicative of an unvaccinated and uninfected felid, or a felid that has not received the FIV vaccine within about 12 weeks before obtaining the sample. 
 
 
     
     
         40 . The method of  claim 39 , further comprising obtaining a second biological sample from the felid detected positive in step (c)(i) at about 10 to 12 weeks after the first biological sample is taken, and repeating step (b), wherein a positive result is indicative of an FIV-infected felid, and a negative result is indicative of an uninfected felid that has received the FIV vaccine. 
     
     
         41 . The method of  claim 39  wherein the first antigen consists of SEQ ID NO:9. 
     
     
         42 . The method of  claim 39  wherein the first antigen consists of SEQ ID NO:20. 
     
     
         43 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:1. 
     
     
         44 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:2. 
     
     
         45 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:3. 
     
     
         46 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:4. 
     
     
         47 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:5. 
     
     
         48 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:6. 
     
     
         49 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:7. 
     
     
         50 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:8. 
     
     
         51 . The method of  claim 39  wherein the first antigen comprises SEQ ID NO:10. 
     
     
         52 . A method for detecting vaccination and/or infection of FIV in felids comprising:
 (a) obtaining a first biological sample from a felid;   (b) contacting the sample with a first antigen consisting of SEQ ID NO:9, consisting of SEQ ID NO:20 or comprising an FIV Env peptide selected from the group consisting of SEQ ID NO:1-8 and 10 under conditions that permit antibody-antigen binding, wherein said first antigen is attached to a solid phase;   (c) contacting the biological sample with a second antigen comprising an FIV Gag polypeptide, wherein the second antigen is attached to a solid phase under conditions that permit antibody-antigen binding,   (d) detecting for antibody-antigen binding, wherein
 (i) a positive result in both step (b) and step (c) is indicative of an FIV-infected felid or a felid that has been vaccinated with a whole-killed FIV vaccine that comprises an inactivated FIV Env protein (“FIV vaccine”) within about 12 weeks before obtaining the sample; 
 (ii) a negative result in both step (b) and step (c) is indicative of an unvaccinated and uninfected felid; 
 (iii) a negative result in step (c) and a positive result in step (b) is indicative of an uninfected felid that has been vaccinated with the FIV vaccine. 
   
     
     
         53 . The method of  claim 52  further comprising obtaining a second biological sample from the felid detected positive in step (d)(i) at about 10 to 12 weeks after the first biological sample is taken, and repeating step (b), wherein a positive result is indicative of an FIV-infected felid, and a negative result is indicative of an uninfected felid that has been vaccinated with the FIV vaccine. 
     
     
         54 . The method of  claim 52 , wherein the FIV Gag polypeptide is FIV p15 or FIV p24. 
     
     
         55 . The method of  claim 52  wherein the first antigen consists of SEQ ID NO:9. 
     
     
         56 . The method of  claim 52  wherein the first antigen consists of SEQ ID NO:20. 
     
     
         57 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO: 1. 
     
     
         58 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:2. 
     
     
         59 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:3. 
     
     
         60 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:4. 
     
     
         61 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:5. 
     
     
         62 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:6. 
     
     
         63 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:7. 
     
     
         64 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:8. 
     
     
         65 . The method of  claim 52  wherein the first antigen comprises SEQ ID NO:10. 
     
     
         66 . A method for determining an FIV infection of FIV in felids comprising:
 (a) obtaining a biological sample from a felid;   (b) contacting the sample with an antigen consisting of SEQ ID NO:9, consisting of SEQ ID NO:20 or comprising an FIV Env peptide selected from the group consisting of SEQ ID NO:1-8 and 10 under conditions that permit antibody-antigen binding;   (c) detecting antibody-antigen binding, thereby determining that the felid has been infected with FIV of has received a whole killed FIV vaccine that comprises an inactivated FIV Env protein within about 12 weeks before obtaining the sample.   
     
     
         67 . The method of  claim 66  wherein the antigen consists of SEQ ID NO:9. 
     
     
         68 . The method of  claim 66  wherein the antigen consists of SEQ ID NO:20. 
     
     
         69 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:1. 
     
     
         70 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:2. 
     
     
         71 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:3. 
     
     
         72 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:4. 
     
     
         73 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:5. 
     
     
         74 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:6. 
     
     
         75 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:7. 
     
     
         76 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:8. 
     
     
         77 . The method of  claim 66  wherein the antigen comprises SEQ ID NO:10.